CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 274 enrolled
Drug / intervention
Capecitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01725386
NCT01725386N/ACompleted
CompareCT.gov

Study on Xeloda® to Document Its Use in Routine Practice in Patients With Metastatic or Advanced Breast Cancer

Hoffmann-La Roche·observational·Posted Nov 12, 2012·Updated Sep 28, 2016

In Brief

An observational study evaluating Capecitabine for Breast Cancer. Completed, enrolled 274 participants across 15 sites.

Detailed Summary

This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesPakistan
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 12, 2012
Enrollment StartMar 1, 2011
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.6 years ago

Interventions

Capecitabinedrug

Oral tablet(s) administered according to prescribing information